World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
46
Citations
9943
World Ranking
4593
National Ranking
2071

Don M. Benson publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Don M. Benson sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 258 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Don M. Benson D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Don M. Benson sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 46 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 1993 - Fellow of the American Phytopathological Society

Overview

Don M. Benson is affiliated with The Ohio State University in the United States and has a research focus primarily within the field of Medicine, with specialization in Hematology, Molecular Biology, Oncology, Transplantation, and Public Health, Environmental and Occupational Health. Their work spans multiple topics including Multiple Myeloma Research and Treatments, Hematopoietic Stem Cell Transplantation, Renal Transplantation Outcomes and Treatments, Acute Lymphoblastic Leukemia research, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, and Acute Myeloid Leukemia Research.

Benson has contributed to numerous publications with frequent outlets including Blood, Transplantation and Cellular Therapy, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, and Cancers.

The recent research papers authored or co-authored by Benson include:

  • Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function, 2021, JCI Insight
  • Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy, 2021, Journal of the National Comprehensive Cancer Network
  • Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation, 2021, Cancers
  • Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies, 2020, Journal of Geriatric Oncology
  • Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients, 2021, Frontiers in Oncology

Frequent co-authors collaborating with Benson are Ashley Rosko, Srinivas Devarakonda, Naresh Bumma, Yvonne A. Efebera, and Nidhi Sharma.

The scientist's work covers a range of subfields related to blood cancers, transplantation, and molecular mechanisms underlying disease and treatment responses. Their research includes focus areas such as early post-transplantation immunosuppression, functional deficits in older adults with hematologic malignancies, and immune regulation within tumor microenvironments.

Benson was honored as a Fellow of the American Phytopathological Society in 1993, indicating recognition within the scientific community.

Best Publications

  • The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

    Don M. Benson;Courtney E. Bakan;Anjali Mishra;Craig C. Hofmeister

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development

    Flavia Pichiorri;Flavia Pichiorri;Sung Suk Suh;Sung Suk Suh;Alberto Rocci;Luciana De Luca

  • CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

    Jianhong Chu;Youcai Deng;Don M. Benson;Shun He

  • Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

    Francois Romagné;Pascale André;Pieter Spee;Stefan Zahn

  • Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

    Shauna M. Collins;Courtney E. Bakan;Gina D. Swartzel;Craig C. Hofmeister

  • Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells

    Jianhua Yu;Min Wei;Brian Becknell;Rossana Trotta

  • The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.

    Wenjuan Dong;Xiaojin Wu;Xiaojin Wu;Shoubao Ma;Shoubao Ma;Yufeng Wang

  • A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

    Norbert Vey;Jean-Henri Bourhis;Nicolas Boissel;Dominique Bordessoule

  • Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

    Andrzej J. Jakubowiak;Don M. Benson;William Bensinger;David S.D. Siegel

  • A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

    Don M. Benson;Craig C. Hofmeister;Swaminathan Padmanabhan;Attaya Suvannasankha

  • IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

    Don M. Benson;Courtney E. Bakan;Shuhong Zhang;Shauna M. Collins

  • Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

    Ian W. Flinn;Brad S. Kahl;John P. Leonard;Richard R. Furman

  • A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

    Thomas Martin;Rachid Baz;Don M. Benson;Nikoletta Lendvai;Nikoletta Lendvai

  • CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Richard R. Furman;John C. Byrd;Jennifer R Brown;Steven E. Coutre

  • A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma

    Don M. Benson;Adam D. Cohen;Sundar Jagannath;Nikhil C. Munshi

  • A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells

    Li Lin;Li Lin;Stephanie Deangelis;Elizabeth Foust;James Fuchs

  • Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

    Brad Kahl;John C. Byrd;Ian W. Flinn;Nina Wagner-Johnston

  • The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.

    Matthew A. Bill;James R. Fuchs;Chenglong Li;Jennifer Yui

  • CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody

    Farrukh T. Awan;Rosa Lapalombella;Rossana Trotta;Jonathan P. Butchar

  • Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells

    Yufeng Wang;Yibo Zhang;Tiffany Hughes;Jianying Zhang

  • A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma

    Khuda D. Khan;Christos Emmanouilides;Don M. Benson;Deborah Hurst

  • The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells

    Tiffany Hughes;Edward L. Briercheck;Aharon G. Freud;Rossana Trotta

Frequent Co-Authors

Steven M. Devine
Steven M. Devine The Ohio State University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
Jianhua Yu
Jianhua Yu City Of Hope National Medical Center
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Jennifer R. Brown
Jennifer R. Brown Harvard University
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Michael R. Grever
Michael R. Grever The Ohio State University
Steven Coutre
Steven Coutre Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare degrees offer diverse career opportunities ranging from clinical practice to research. Accelerated Nursing programs such as absn programs with high acceptance rates provide a fast track to becoming a registered nurse, which can be an excellent stepping stone into immunology-related roles in patient care or clinical trials.

Entry-level nursing positions also have pathways that align well with immunology, with easy lpn programs to get into offering accessible options for gaining essential healthcare experience. These credentials allow professionals to engage directly with patients, enhancing understanding of immune-related conditions.

For advanced practice, pursuing a Family Nurse Practitioner degree can deepen clinical expertise. The easiest fnp program options often blend flexibility and quality, making them suitable for those balancing education with work. This specialization supports roles that involve immunological assessments and treatments.

Additionally, mental health is closely connected to the immune system, and online PMHNP degree programs can be pivotal. Exploring pmhnp programs online with best clinical placement ensures practical experience and a strong foundation for those interested in neuroimmunology or psychoneuroimmunology careers.

Best Scientists Citing Don M. Benson

Trending Scientists

Recently Published Articles